Aug. 27 at 12:46 PM
$ALLR The market thinks ALLR owns a cancer drug. What it may actually own is the oncology equivalent of a cheat code: a test that tells you which patients are worth treating before the drug bill starts printing.
If DRP proves it can consistently find responders, this is not a
$30 million microcap platform—it’s a
$1 billion precision-oncology tollbooth.
Big Pharma spends billions discovering drugs. ALLR’s DRP could tell them which of those drugs deserve a second life—and which ones should be buried behind the lab.
Stenoparib is the rocket. DRP is the guidance system. And the market is currently valuing the company like it owns neither.
